Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TOMZ | 8-K | bearish | 8/10 | TOMI Environmental Solutions received a delisting notice from Nasdaq on May 19, 2026, for failing to regain compliance w | May 20, 2026 |
| PHAT | PRESS-RELEASE | neutral | 3/10 | Phathom Pharmaceuticals announced the presentation of 31 vonoprazan-related abstracts at DDW 2026, including a Phathom-s | May 20, 2026 |
| MSLE | 6-K | neutral | 2/10 | Satellos Bioscience Inc. filed its management information circular and proxy materials for the June 17, 2026 annual gene | May 20, 2026 |
| DYN | PRESS-RELEASE | bullish | 7/10 | Dyne Therapeutics initiated the Phase 3 FORZETTO trial of z-rostudirsen (DYNE-251) in Duchenne muscular dystrophy patien | May 20, 2026 |
| QUCY | PRESS-RELEASE | neutral | 4/10 | Quantum Cyber filed a provisional patent application for its SCOUT-AX6 GUARDIAN, an amphibious autonomous ground vehicle | May 20, 2026 |
| VXRT | DEFA14A | neutral | 4/10 | Vaxart filed additional definitive proxy soliciting materials (DEFA14A) for its 2026 Annual Meeting, facing a contested | May 20, 2026 |
| VXRT | DEFA14A | neutral | 4/10 | Vaxart filed additional definitive proxy soliciting materials in connection with its 2026 Annual Meeting scheduled for J | May 20, 2026 |
| ROIV | 8-K | mixed | 6/10 | Roivant reported Q4 FY2026 non-GAAP loss per share of -$0.317, beating consensus of -$0.38, but revenue of $2.5M missed | May 20, 2026 |
| IMVT | 8-K | mixed | 6/10 | Immunovant reported fiscal Q4 2026 results with a net loss of $147.9M ($0.73/share), wider than the $106.4M loss a year | May 20, 2026 |
| ROIV | PRESS-RELEASE | mixed | 7/10 | Roivant Sciences reported Q4 FY2026 GAAP EPS of $0.43 (including a $770M litigation settlement gain) vs consensus of -$0 | May 20, 2026 |
| IMVT | PRESS-RELEASE | bullish | 7/10 | Immunovant reported Q4 FY2026 net loss of $0.73/share, wider than prior year's $0.64 loss, driven by increased R&D spend | May 20, 2026 |
| PCRX | PRESS-RELEASE | mixed | 7/10 | Pacira BioSciences issued a press release urging stockholders to vote for its board nominees at the June 9 annual meetin | May 20, 2026 |
| SCNI | EFFECT | bearish | 6/10 | Scinai Immunotherapeutics' shelf registration on Form F-3 (File No. 333-295698) was declared effective by the SEC on May | May 20, 2026 |
| BLTE | PRESS-RELEASE | mixed | 6/10 | Belite Bio reported Q1 2026 GAAP EPS of -$0.68, missing the -$0.64 consensus by 6.3%, with net loss widening to $26.9M f | May 20, 2026 |
| ARTV | CLUSTER | bearish | 5/10 | CEO Fred Aslan and CMO Subhashis Banerjee sold a combined $308K in open-market sales on May 19, 2026, just 11 days after | May 19, 2026 |
| MGTX | 144 | neutral | 3/10 | CEO Alexandria Forbes filed a Form 144 to sell 62,000 ordinary shares with an estimated value of $568,540, representing | May 19, 2026 |
| TNYA | CLUSTER | neutral | 2/10 | Two Tenaya insiders (CMO and SVP Finance) sold a combined $3.7K worth of shares on May 18, 2026, all at ~$0.79 per share | May 19, 2026 |
| EXEL | CLUSTER | neutral | 3/10 | Exelixis CFO and General Counsel sold a combined ~$2.08M in open-market shares on May 18, 2026, alongside a large non-ca | May 19, 2026 |
| PHVS | CLUSTER | neutral | 4/10 | Two C-suite insiders at Pharvaris sold a combined $560K in open-market sales on May 15, 2026, just 11 days after the com | May 19, 2026 |
| SXTPW | 3 | neutral | 3/10 | Eric Francois filed a Form 3 initial statement of beneficial ownership reporting zero securities owned in 60 Degrees Pha | May 19, 2026 |
| PCSA | CLUSTER | bullish | 5/10 | Four C-suite insiders at Processa Pharmaceuticals (PCSA) collectively purchased $19K worth of shares on May 15, 2026, at | May 19, 2026 |
| IMUX | 3 | neutral | 2/10 | Michael W. Bonney filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting no securities bene | May 19, 2026 |
| PCSA | CLUSTER | bullish | 5/10 | Six PCSA insiders, including the CEO, CFO, and four other C-suite officers, made clustered open-market purchases totalin | May 19, 2026 |
| MNPR | 8-K | bullish | 6/10 | Monopar announced the peer-reviewed publication of Phase 2 study results in Hepatology Communications demonstrating that | May 19, 2026 |
| VXRT | PREC14A | neutral | 4/10 | Vaxart filed a preliminary proxy statement for its 2026 annual meeting, facing a contested director election from stockh | May 19, 2026 |
| ANVS | 424B5 | bearish | 7/10 | Annovis Bio filed a preliminary 424B5 for an underwritten offering of common stock and warrants, with no final pricing d | May 19, 2026 |
| PTCT | CLUSTER | neutral | 2/10 | Two insiders at PTC Therapeutics sold a combined $220K of stock shortly after a strong Q1 earnings beat and raised guida | May 19, 2026 |
| AIM | 424B5 | mixed | 5/10 | AIM ImmunoTech filed a 424B5 to suspend its equity distribution agreement (ATM) with Maxim Group, halting further sales | May 19, 2026 |
| RLAY | 424B5 | bearish | 6/10 | Relay Therapeutics is filing a 424B5 to offer $175 million of common stock (up to $201.25 million with the underwriters' | May 19, 2026 |
| RGC | 424B5 | bearish | 6/10 | Regencell Bioscience is raising ~$20M in a registered direct offering of 985,222 shares at $20.30 each, a 27% discount t | May 19, 2026 |